- Home
- FRO vs AKRO Comparison
FRO vs AKRO Comparison
Compare FRO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRO
- AKRO
- Stock Information
- Founded
- FRO 1985
- AKRO 2017
- Country
- FRO Cyprus
- AKRO United States
- Employees
- FRO N/A
- AKRO N/A
- Industry
- FRO Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FRO Consumer Discretionary
- AKRO Health Care
- Exchange
- FRO Nasdaq
- AKRO Nasdaq
- Market Cap
- FRO 3.6B
- AKRO 2.8B
- IPO Year
- FRO N/A
- AKRO 2019
- Fundamental
- Price
- FRO $17.11
- AKRO $42.39
- Analyst Decision
- FRO Strong Buy
- AKRO Strong Buy
- Analyst Count
- FRO 3
- AKRO 9
- Target Price
- FRO $23.33
- AKRO $76.29
- AVG Volume (30 Days)
- FRO 2.8M
- AKRO 1.1M
- Earning Date
- FRO 05-29-2025
- AKRO 05-16-2025
- Dividend Yield
- FRO 10.40%
- AKRO N/A
- EPS Growth
- FRO N/A
- AKRO N/A
- EPS
- FRO 2.23
- AKRO N/A
- Revenue
- FRO $2,050,385,000.00
- AKRO N/A
- Revenue This Year
- FRO N/A
- AKRO N/A
- Revenue Next Year
- FRO $12.01
- AKRO N/A
- P/E Ratio
- FRO $7.71
- AKRO N/A
- Revenue Growth
- FRO 13.77
- AKRO N/A
- 52 Week Low
- FRO $12.40
- AKRO $17.86
- 52 Week High
- FRO $29.39
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FRO 58.54
- AKRO 52.42
- Support Level
- FRO $15.83
- AKRO $41.60
- Resistance Level
- FRO $18.33
- AKRO $46.47
- Average True Range (ATR)
- FRO 0.52
- AKRO 2.05
- MACD
- FRO 0.17
- AKRO 0.37
- Stochastic Oscillator
- FRO 65.34
- AKRO 55.60
About FRO Frontline Plc
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.